Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Depreciation & Amortization (CF): 2011-2025

Historic Depreciation & Amortization (CF) for Abeona Therapeutics (ABEO) over the last 15 years, with Sep 2025 value amounting to $608,000.

  • Abeona Therapeutics' Depreciation & Amortization (CF) rose 24.85% to $608,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 13.75%. This contributed to the annual value of $2.0 million for FY2024, which is 12.41% down from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Depreciation & Amortization (CF) is $608,000, which was up 11.76% from $544,000 recorded in Q2 2025.
  • Abeona Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $824,000 during Q2 2021, with a 5-year trough of $487,000 in Q2 2024.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $534,000 (2025), whereas its average is $543,455.
  • Per our database at Business Quant, Abeona Therapeutics' Depreciation & Amortization (CF) plummeted by 60.44% in 2021 and then rose by 24.85% in 2025.
  • Abeona Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $807,000 in 2021, then declined by 9.67% to $729,000 in 2022, then crashed by 32.65% to $491,000 in 2023, then increased by 9.78% to $539,000 in 2024, then climbed by 24.85% to $608,000 in 2025.
  • Its last three reported values are $608,000 in Q3 2025, $544,000 for Q2 2025, and $534,000 during Q1 2025.